

IMI Projects Communication Event - 2 April 2019


Karl Ferrand - EU Open Data and CORDIS - EU Publications Office

## CORDIS in European research

- First EU framework programme for research in 1984
- CORDIS launched in 1990 and first EU website in 1994
- CORDIS is the EC's primary public repository and portal for all EUfunded research projects and results
- FP4, FP5, FP6, FP7: web services and applications
- Horizon 2020: partnership with Common Support Centre (DG RTD J5)
- Part of EC strategy for Dissemination and Exploitation of research results
- Focus: bring research results to professionals in the field




### **CORDIS** website



Much improved since 1994...

New responsive website: Highlight articles/publications Better search



18 March 2019



### Project & Results



#### Latest updated projects

Acronym	Title	ID	Last update
CaLA	The Capillary Lock Actuator: A novel bistable microfluidic actuator for cost-effective high- density actuator arrays suitable for large-scale graphical tactile displays	816006	19 March 2019
NatDyReL	Utilizing Natural Dynamics for Reliable Legged Locomotion	819358	19 March 2019
GREENER	InteGRated systems for Effective ENvironmEntal Remediation	826312	19 March 2019
ESTRO	Experimental and theoretical aSsessmenT of laminaR flow rObusteness at high mach and reynolds numbers	831809	19 March 2019
ASSALA	Advanced Simulation Solutions Applied to Quality Control of Laser Deposited Metals	831857	19 March 2019
NADiA	Novel Air Distribution Approaches	831716	19 March 2019
DELTA	Development and Execution of innovative test procedures for vaLidation of Thermoplastic Aircraft fuselage panels	831862	19 March 2019
CO3	COld sprayed COating on COmposite	831979	19 March 2019
THERMAC	Thermal-aware Resource Management for Modern Computing Platforms in the Next Generation of Aircraft	832011	19 March 2019
DNACom	Compartmentalized DNA Computers for In-Vitro Diagnostic Applications	835883	19 March 2019
FluidER	Real time Optoelectronic Sensors for Electro- Actuator Hydraulic Fluid Contamination Monitoring	831998	19 March 2019

All public information submitted by projects and held by the EC, from FP1 to H2020.

Visualisations: Horizon Dashboard and H2020 Collaboration Map

Open datasets: download all projects for H2020, FP7 and earlier



# **Project factsheets**



miatric Ratings using Intermediate Stratified Markers - Sofia ref.: 115916

act Sheet

Reporting Results

#### Objective

The current nosology of neuropsychiatric disorders allows for a pragmatic approach to treatment choice, regulation and clinical research. However, without a biological rationale for these disorders, drug development has dramatically stagnated in the past decades. In a coordinated effort encompassing academic experts, SMEs, patient and family organizations, regulators, ECNP and EFPIA partners, this project aims to develop a quantitative biological approach to the understanding and classification of neuropsychiatric diseases to accelerate the discovery and development of better treatments for patients. This project will concentrate on Schizophrenia (SZ), Alzheimer's disease (AD), and Major Depression (MD), as these disorders share part of their symptomatology, in particular social withdrawal and certain cognitive deficits, such as deficits in attention, working memory and sensory processing. By applying innovative technologies (e.g. EEG, cognitive tasks, (f)MRI,

smartphone monitoring, and (epi-)genetics) to deep phenotype a clinical cohort of SZ and AD patients combined with a wider analysis of existing clinical data sets from major European and global disease cohorts that also include MD, we will define a set of quantifiable biological parameters best able to cluster and differentiate SZ, AD, and MD patients that do, or do not, exhibit social withdrawal. First, by mining large European SZ, AD and MD cohort datasets with already available social and cognitive proxy measures, and, second, by obtaining objective measures of social exploration levels (using a novel smartphone application), phenotypic relationships with social and cognitive measures will be further tested. For instance we might predict that socially withdrawn individuals may have lower cognitive functioning and poorer clinical course compared to those who are more socially engaged.

#### Programme(s)

H2020-EU.3.1.7.4. - Diabetes

#### Topic(s)

IMI2-2015-03-03 - Linking Clinical Neuropsychiatry and Quantitative Neurobiology

#### Call for proposal

H2020-JTI-IMI2-2015-03-two-stage

See other projects for this call

#### Funding Scheme

IMI2-RIA - Research and Innovation action





# Coordinator RUKSURVI ISCITET GROBBICEN Activity Type Boventrads Springer discording Flacation 22 104-991 Entitlationasts Whomas Contact the approximation

Participants (22

set aspra	abetically 0 Sort by EU Contribution 0		Expand
童	P1VITAL LIMITED  SE United Kingdom	EU Contribution € 1 226 586	
童	STICHTING KATHOLIEKE UNIVERSITEIT  Netherlands	EU Contribution € 840 000	
9	CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA	EU Contribution	
38.	EN RED M.P. Spain	€ 648 000	
<b>a</b>	ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA	EU Contribution	
M	■ Etaly	€ 100 000	
亩	STICHTING VUMC	EU Contribution	
	Netherlands	€ 775 000	
亩	BIOTRIAL	EU Contribution	
	France	€ 350 000	
B	DRUG TARGET ID BV	EU Contribution	
	Netherlands	€ 200 000	
-	THE UNIVERSITY OF EXETER	EU Contribution	
	United Kingdom	€ 90 000	
命	SBGNEURO LTD	EU Contribution	
M.	SHE United Kingdom	€ 490 000	
*	Concentris Research Management GmbH	EU Contribution	
200	Germany	€ 315 000	
命	ACADEMISCH ZIEKENHUIS LEIDEN	EU Contribution	
MI.	Netherlands	€ 350 000	
亩	ERASMUS UNIVERSITAIR MEDISCH CENTRUM	EU Contribution	
-	ROTTERDAM Netherlands	€ 100 000	
â.	STICHTING BURO ECNP	EU Contribution	
M	Netherlands .	€ 170 000	
-	EUROPESE FEDERATIE VAN FAMILIEVERENIGINGEN VAN		
	PSYCHIATRISCH ZIEKE PERSONEN IVZW  Belgium	€ 18 563	
4	BOEHRINGER INGELHEIM INTERNATIONALGMBH		
38.	Germany		
亩	NOVARTIS PHARMA AG		
	Switzerland		
育	PFIZER LIMITED		
	Linited Kingdom		
亩	F. HOFFMANN-LA ROCHE AG		
	Switzerland		
Ĥ	TAKEDA DEVELOPMENT CENTRE EUROPE LTD.		
亩	Eli Lilly and Company Limited		
童	JANSSEN PHARMACEUTICA NV		
*	UNIVERSITAIR MEDISCH CENTRUM UTRECHT	EU Contribution	
-	Netherlands	€ 301 870	

Project factsheet is based on grant agreement: objective/abstract, topic, call, scheme, dates, funding, participants, etc

Changes usually require an amendment (but send us your website URL)



# Project reporting



Psychial in Ratings using Intermediate Stratified Markers - Sofia ref.: 115916

Periodic Reporting for period 1 - PRISM (Psychiatric Ratings using Intermediate Stratified Markers: providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and

Reporting period: 2016-04-01 to 2017-03-31

#### Summary of the context and overall objectives of the project

Most mental health conditions are still classified and diagnosed solely based on the symptoms observed, as there are few objective biomarkers for these conditions as there are for other conditions, such as diabetes. Many different neuropsychiatric diseases share symptoms, which makes it difficult to understand what the underlying biological cause of a specific disease is. For example, we do not really have an idea how, if at all, the biological cause for social withdrawal in Alzheimer's disease differs from that in schizophrenia.

This lack of understanding of the root biological causes is one of the reasons behind the dramatic slowdown in the development of new drugs to treat neuropsychiatric disorders.

Historically, many of the major drug classes for psychiatric disorders were discovered as a consequence of chance observations in human studies, an approach that suffers from a high rate of attrition and risk of drug candidate failures during development.

Modern drug design aims to reduce this risk of attrition by altering a known biological process and closely monitoring and quantifying the treatment effects of doing this.

The emergence of new ways of measuring brain activity (e.g. functional Magnetic Resonance Imaging (fMRI) of the brain which registers blood flow to functioning areas of the brain) is for the first time opening the door to applying this type of drug discovery to mental health conditions.

Therefore, the overall objective of this project is to develop a quantitative biological approach to the understanding and classification of neuropsychiatric diseases to accelerate the discovery and development of better treatments for patients.

The concept of our project is to define a set of quantifiable biological parameters for social withdrawal and cognitive deficits to cluster and differentiate schizophrenia (SZ). Alzheimer's disease (AD), and to a lesser degree, patients with major depressive disorder (MD). The following specific objectives will be addressed:

- 1. Proof-of-concept (PoC) analyses to cluster and differentiate SZ and AD patients on the basis of quantitative biological parameters.
- 2. Explore dimensional relationships between pathology (e.g. cognitive deficits) and social withdrawal.
- 3. Develop deeper understanding of the quantitative biology of social withdrawal using clinical data from SZ, AD and MD patients and by establishing a network of pre-clinical research sites able to perform high quality back-translation studies.
- 4. Develop a path towards recognition of social withdrawal as a registrable symptom across disorders

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)




Project information **PRISM** Grant agreement ID: 115916 Project website Ongoing project Start date End date 1 April 2016 31 March 2019 Funded under H2020-EU.3.1.7.4. £ 17 099 552 RIJKSUNIVERSITEIT GRONINGEN - Netherlands

Projects' periodic and final publishable summaries from SyGMa (H2020) or SESAM (FP7).

Be aware of confidential information and image copyright.



# **Project Results**



**Project information PRISM** Grant agreement ID: 115916 Project website Ongoing project Start date Fnd date 1 April 2016 31 March 2019 H2020-EU.3.1.7.4. Overall budget: EU contribution € 8 080 000 Coordinated by RIJKSUNIVERSITEIT GRONINGEN Netherlands

Also from continuous reporting by projects: *public* deliverables only.

For FP7 publications: on the fly query to OpenAIRE



### Results in Brief



DRIVING A:-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE

Fact Sheet





Recommendations on driving antibiotic R&D and helping to fight antimicrobial resistance

Antibiotic resistance is one of the biggest threats to global health, and it's only getting worse. Innovation in this area is lacking because few big pharma companies are willing to invest in R&D as a result of low returns and high risks.



HEALTH SOCIETY INDUSTRIAL TECHNOLOGIES



It is estimated that antibacterial drug resistance costs the EU at least EUR 1.5 billion and about 25 000 lives every year. The development of new drugs to treat resistant infections is falling behind. New economic models offering incentives that directly support R&D and reward successful outcomes from R&D for the discovery and development of novel antibiotics are long overdue. These models will also need to reconcile such incentives with responsible antibiotic use and access.

The EU and industry-funded project DRIVE-AB aimed to "transform the way policymakers stimulate antibiotic innovation while ensuring that these new antibiotics are used sustainably and are equitably available to meet public health needs" says Judith Hackett the project's coordinator. To build policy recommendations and incentivise antibiotic R&D DRIVE-AB used a research-based multidisciplinary approach involving a broad range of stakeholders from academic institutions research organisations and pharmaceutical/biotechnology industries.

Furthermore, project partners defined standards and metrics for responsible use of antibiotics and identified antibiotic-related public health priorities. They also calculated the societal value of having new antibiotics available for these priorities. In addition, the project team developed and costed new economic models to promote the desired antibiotic innovation and sustainable use of the resulting novel antibiotics

Incentives to revitalise antibiotic pipeline and boost innovation

DRIVE-AR assessed more than 30 different economic incentives. It considered how each one of these would affect antibiotic innovation, sustainable use and equitable availability. One key incentive is the market entry reward, which aims to create an attractive market for investment in antibiotic R&D by attracting increased private sector funding and supporting sustainable R&D investment. A model developed by the project estimates that a market entry reward of at least EUR 850 million per antibiotic globally could quadruple the number of new antibiotics entering the market in the next 30 years.



This project is featured in...



Written by CORDIS science journalists with project coordinators


Highlight results at the end of the project and what's next

Six languages

Many are included in CORDIS Results Packs or Research\*eu magazines



# Project News & Multimedia



For ongoing projects:

By CORDIS journalists based on public sources or contacts

By projects via CORDIS Wire



# How to promote your project on CORDIS

CORDIS Wire: just sign up and get started

Twitter: mention @CORDIS\_EU and we'll retweet to 27k followers – or send us your team photo for our banner

News or Results in Brief: have our journalists write an article

Contact: editorial@cordis.europa.eu





### **CORDIS Results Packs**

Multilingual collections of up-to-date articles that focus on a specific theme, bringing results that you can apply in your domain

36 CORDIS packs so far

Web, PDF and print editions

Driven by client needs at EC, EA and JUs




# Results pack brochures

















# Research\*eu magazines





Our regular magazine highlights the most promising project outcomes in a range of domains, with a focus on a particular theme in every issue



SPECIAL FEATURE

#### From Asimov to all around us: Welcome to the robot revolution

Robots are a staple of science-fiction, with two of the most famous examples being the novel 1, Robot by the widely acclaimed Isaac Asimov, and Ridley Scott's 1982 cinematic masterpiece 'Bladerunner', with a plot focused on a group of fugitive 'replicants', synthetic androids so advanced that they look, sound and act entirely like humans but with superior strength, speed and agility.

Read more

Download

人 PDF

Print edition

Recent issues













See all Research^eu magazines





10 times per year

Web, PDF, print

Special feature each issue

Free worldwide postal subscription



### News & Events

European CORDIS Bringing you the results of EU reach and innovation framework programmes since 1990: Horizon 2020, FP7 and Commission

HOME RESULTS PACKS PROJECTS & RESULTS RESEARCHYEU MAGAZINES NEWS & EVENTS ABOUT US

Sign in

Filter news by: V

#### Latest CORDIS news



#### New technology aims to boost wind energy efficiency in Europe



SCIENTIFIC ADVANCES

How did the wild dogs of Tanzania disappear? Study offers new explanation

18 March 2019



Groundbreaking method creates better and cheaper nanochips

15 March 2019

#### UPCOMING EVENTS

#### RECENTLY ADDED

European Transport and Mobility Forum Launch Event

25 March 2019 to 25 March 2019

Belgium

By: Deep Blue

DESIGNING NEW INCLUSIVE MOBILITY SOLUTIONS - HiReach MULTIDISCIPLINARY IDEATION

27 March 2019 to 28 March 2019

Belgium

By: INTRASOFT International on behalf of the HiReach project

REMOURBAN webinar "High Performance District: Deep retrofitting, low temperature district heating/cooling\*

28 March 2019 to 28 March 2019

Turkey

By: youris.com EEIG

Conference in French: Recent development on transport of molecules across cell membranes by Sandrine

1 April 2019 to 1 April 2019

By: Interdisciplinary European Academy of Sciences - Académie Européenne Interdisciplinaire des Sciences

ROS-Industrial Training (EU)

1 April 2019 to 5 April 2019

Stuttgart, DE

By: CORDIS

SYNERGI is THE event that gives an insight into neutron and synchrotron characterisation techniques for R&D.

1 April 2019 to 1 April 2019

France

By: Institut Laue Langevin

#### Latest news from Wire contributors



From ground to sky to detect water leaks

19 March 2019



A novel approach of machine learning identifies patients at risk of losing kidney transplants due to a common pathology

18 March 2819



SCIENTIFIC ADVANCES

International Women's Day: Female scientists share their thoughts on gender balance in modern research

18 March 2019



Imaging data reveals nanomedicines in lungs

18 March 2019



The P.R.I.T.® lung model to test nanoparticle-based drugs

18 March 2019



NEW PRODUCTS AND TECHNOLOGIES

Confront antibiotic resistance with a better diagnostic system

18 March 2019

See all Wire news

2 April 2019 to 2 April 2019 Romania By: Institut Laue Langevin See all upcoming events

Wire: publish your news and eve



See all on Twitter

GREAT SUCCESS in TECNALIA Stand,

66 Thanks for all your visits. See you tomorrow. \* Stand 513 @LOPECMunich


explaining all our Functional Print innovations!

bit.ly/2TgtMQN pic.twitter.com/det03Q82Fs

6 E W



### Personalised services



#### Latest Results in Brief

Summaries of the main outcomes at the end of each project, explaining the achievements and shining a spotlight on the next steps








### Create your account:

- Free magazine subscription
- Email notifications
- Publish news and events via CORDIS Wire



# Search and reuse of open data






Visualisations

INVISUALISE CORDIS H2020 organisations' collaboration network

### How CORDIS works

CORDIS overview: data flows, systems and actors





# **CORDIS** in numbers

	2018
	Total
Number of visits	4 228 169
Number of pages consulted	14 092 455
Number of Results in Brief written about FP7 and Horizon 2020 research results	1 472
User satisfaction rate (percentage of neutral and positive opinions expressed in the annual user survey)	93.07%
Number of Horizon 2020 research reports available on CORDIS	7 497
Number of postal subscribers to the research*eu Results magazine	4 401
Availability of the CORDIS website 24/7 [quarterly average]	99.19%
Number of visitors	3 315 679
Social media Twitter followers	26 322




### **CORDIS** on Social Media



twitter.com\cordis\_eu



youtube.com/user/CORDISdotEU



instagram.com/cordis\_eu/

Also post on Facebook and LinkedIn

<u>facebook.com/EULawandPublications/</u>
<u>linkedin.com/company/publications-office-of-the-european-union/</u>
<u>linkedin.com/showcase/european-commission-joint-research-centre/</u>



### What's next for CORDIS?

- EuroSciVoc taxonomy: classification by field of science
- Linked Open Data ontology: connect EC data with open science (including EOSC) and track results
- Diversity of thematic articles and publications
- Improve web user experience
- Outreach to target audiences: professionals, networks, industry, investors, innovators
- Prepare for Horizon Europe to maximise impact









